Study wrapper · #118
Formulation Engineering of Oral Semaglutide Tablets: Unleashing Gastric Intestinal Permeation with Sodium Caprate.
Editor's note
A preclinical formulation study, useful for drug-delivery scientists but not a clinical result. Oral semaglutide (Rybelsus) depends on the absorption enhancer SNAC and its narrow gastric mechanism; here the researchers tested whether sodium caprate (C10), a medium-chain fatty acid, could deliver comparable systemic exposure in an immediate-release tablet. Across Caco-2 cell transport, rat pharmacokinetics, and finally beagle dogs (14 mg), an optimized monolayer C10 tablet produced blood-exposure parameters that overlapped with the SNAC reference and showed high dissolution similarity to Rybelsus. That is a coherent, multi-step feasibility signal for an alternative enhancer platform. The limits are important: these are cell and animal models, human data are needed before clinical conclusions can be drawn, small-animal PK does not guarantee human bioavailability given semaglutide's notoriously variable oral absorption, and no efficacy or safety endpoints were tested. Read it as encouraging proof-of-concept for formulation science, not evidence about patient outcomes.
Plain-language abstract
This is a laboratory and animal study about how to build a better pill version of semaglutide. The existing oral form (Rybelsus) needs a special helper ingredient called SNAC to get the peptide absorbed from the stomach, but SNAC has limitations. The researchers tested whether a different helper, sodium caprate (C10), a type of fatty acid, could get similar amounts of the drug into the bloodstream. They first checked C10's basic chemical properties, then studied how well the drug crossed a layer of human gut cells in a dish, then measured drug levels in rats, and finally tested an optimized tablet in beagle dogs at a 14 mg dose, comparing it against the standard SNAC product. C10 increased absorption in a dose-related way and reached blood levels similar to SNAC at matching doses. Among several tablet designs, a single-layer tablet most closely matched how Rybelsus dissolves, and in dogs its blood-level measurements overlapped with the standard product. The authors conclude C10 is a feasible alternative helper for oral peptide pills. Because this was done in cells and animals, human studies would be needed to confirm it works in people.